Whatman's Biometra to Resume Selling Thermocyclers; Firm Fires CEO | GenomeWeb
The original headline mistakenly said Biometra will resume selling its thermocycler business. In fact it will resume selling the instruments.
 
NEW YORK (GenomeWeb News) — Whatman today said it has settled a lawsuit involving its Biometra subsidiary that will enable it to resume selling thermocyclers.
 
The company also said it is firing CEO Bill Emhiser immediately for “disappointing trading” last year. He will be replaced by former Innovata CEO Kieran Murphy.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.